FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | |
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Vong John | | | | | 2. Issuer Name and Ticker or Trading Symbol Apollo Medical Holdings, Inc. [AMEH] | | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | | |
|--|---|--|---|--|--|--|--|-------|---|-------|--|--------------------|--------------------|---|---|--|--|--|---|--|
| (Last) 1668 S. GARFI | (First) | , | (Middle) | | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/12/2022 | | | | | | | | | ive title Chief Ac | Other (specify below) counting Officer | | | |
| 2ND FLOOR | | | | | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | |
| (Street) ALHAMBRA | CA | 91 | 801 | | | | | | | | | | | | Form file | d by More | than O | ne Reportin | g Person | |
| (City) | (State) | (Zi | o) | | | | | | | | | | | | | | | | | |
| | | Та | ble I - Non | -Der | ivativ | e S | ecuritie | s Acq | uired, l | Disp | osed of, | or Be | enefic | ially Ov | vned | | | | | |
| | | | | 2. Transaction Date (Month/Day/Year) | | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a | | | | Securities Beneficially Following | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) | | nership Direct (D) irect (I) 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | | | Code | v | Amount | | A) or D) | Price | (Instr. 3 and | | | | (111501.4) | |
| Common Stock | | | | 12/ | 12/12/2022 | | | | A | | 1,388 | 1) | A | \$ <mark>0</mark> | 5,159 | | | D | | |
| Common Stock | | | | 12/ | 12/12/2022 | | | | A | | 1,388 | 8 ⁽²⁾ A | | \$ <mark>0</mark> | 6,5 | 6,547 | | D | | |
| Common Stock 1 | | | | 12/ | /12/2022 | | | | A | | 694(3) | | A | \$ <mark>0</mark> | 7,241 | | D | | | |
| Common Stock | | | 12/ | 2/12/2022 | | | | A | | 694(4 | | A | \$ <mark>0</mark> | 7,935 | | | D | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Dat if any (Month/Day/Y | te, | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exerci Expiration Dat (Month/Day/Ye | | te Securities Under | | derlying curity | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficia Owned Following Reported Transacti | e s lly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| Evaluation of Do | | | | | Code | v | (A) (D) | | | | Expiration Date | Title | | Amount or Number of Shares | | (Instr. 4) | (0) | | | |

Explanation of Responses:

- 1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2015 Equity Incentive Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, the shares of restricted stock shall vest in four equal annual installments beginning on November 30, 2023 and upon achievement of a pre-established performance goal on or before April 1, 2023.
- 2. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2015 Equity Incentive Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, the shares of restricted stock shall vest in four equal annual installments beginning on November 30, 2023 and upon achievement of a pre-established performance goal on or before July 1, 2023.
- 3. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2015 Equity Incentive Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, 519 shares shall vest in three equal annual installments beginning on November 30, 2023. The remaining 175 shall vest on November 30, 2026. Such vesting is subject to achievement of a pre-established performance goal on or before April 1, 2023.
- 4. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2015 Equity Incentive Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, 519 shares shall vest in three equal annual installments beginning on November 30, 2023. The remaining 175 shall vest on November 30, 2026. Such vesting is subject to achievement of a pre-established performance goal on or before November 30, 2026.

Remarks

/s/ John Vong

12/13/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.